NCT00555906 · OUTCOME

European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (EORTC QLQ-C30): Phase 2

An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma. · Source last updated 2015-03-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEAN
Unit: units on a scale
Interval / dispersion: 95% Confidence Interval
Time frame: C1D1 (baseline), C1D8, C1D15, C2D1, C3D1, C4D1, C5D1, C6D1, C7D1, C8D1, C9D1, C10D1, C11D1, C12D1, C13D1, C14D1, C15D1, C16D1, C17D1, C18D1, C19D1, C20D1, C21D1, C22D1, End of Treatment (assessment at early withdrawal occurring up to Cycle 22)

What was measured

EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnea, appetite loss, insomnia, constipation, diarrhea and financial difficulties). Most questions used 4 point scale (1 'Not at all' to 4 'Very much'); 2 questions used 7-point scale (1 'very poor' to 7 'Excellent'). Scores for functional scales, global health status and symptom scales were calculated as an average of individual items, transformed to 0-100 scale; higher score=better level of functioning, health status or greater degree of symptoms. Score of the single items were transformed to 0-100 scale; higher score=greater degree of symptom/difficulty.

Analysis population: Patient Reported Outcomes (PRO) analysis set included all enrolled participants who received study treatment, had a baseline PRO assessment, and completed at least 1 on-study PRO assessment. Here 'n' signifies those participants who were evaluable at specified time points for each arm, respectively.

Groups in this outcome

Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)

Palbociclib (PD 0332991) 100 mg capsule orally once daily for 12 days followed by 9 days off-treatment in a 21-day cycle along with bortezomib 1.0 mg/m\^2 intravenous injection and dexamethasone 20 mg tablet orally 30 minutes prior to bortezomib injection on Day 8, 11, 15 and 18 of 21-day cycle (schedule B) during Phase 2 of the study. Treatment was continued until any of the following withdrawal criteria was met: disease progression (unless the investigator judged that participant could still derive clinical benefit from continuing the treatment and the risk/benefit was still favorable), unacceptable toxicities, need for surgery or radiation therapy considered due to progressive disease by investigator, investigator conclusion that it is in the participant's best interest to discontinue therapy, need for anti-cancer therapy, lost to follow-up, withdrawal from treatment, or withdrawal of consent.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	27

Reported measurements

C1D1: Global Health Status (n=27)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	60.80	Not reported	50.7	70.9	Not reported

C1D1: Physical Functioning (n=27)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	64.20	Not reported	55.6	72.8	Not reported

C1D1: Role Functioning (n=27)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	59.88	Not reported	46.8	73.0	Not reported

C1D1: Emotional Functioning (n=27)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	70.37	Not reported	59.8	80.9	Not reported

C1D1: Cognitive Functioning (n=27)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	72.22	Not reported	62.0	82.4	Not reported

C1D1: Social Functioning (n=27)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	69.14	Not reported	57.6	80.7	Not reported

C1D1: Fatigue (n=27)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	29.63	Not reported	19.1	40.2	Not reported

C1D1: Nausea and Vomiting (n=27)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	6.79	Not reported	2.2	11.4	Not reported

C1D1: Pain (n=27)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	35.80	Not reported	22.0	49.6	Not reported

C1D1: Dyspnea (n=27)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	32.10	Not reported	21.4	42.7	Not reported

C1D1: Insomnia (n=27)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	43.21	Not reported	29.1	57.3	Not reported

C1D1: Appetite Loss (n=27)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	20.99	Not reported	8.8	33.2	Not reported

C1D1: Constipation (n=27)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	27.16	Not reported	12.5	41.8	Not reported

C1D1: Diarrhea (n=27)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	11.11	Not reported	4.8	17.4	Not reported

C1D1: Financial Problems (n=26)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	33.33	Not reported	17.2	49.5	Not reported

C1D8: Global Health Status (n=26)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	60.58	Not reported	51.4	69.7	Not reported

C1D8: Physical Functioning (n=26)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	67.18	Not reported	58.2	76.2	Not reported

C1D8: Role Functioning (n=26)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	59.62	Not reported	47.0	72.3	Not reported

C1D8: Emotional Functioning (n=26)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	72.76	Not reported	61.5	84.0	Not reported

C1D8: Cognitive Functioning (n=26)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	69.87	Not reported	56.8	82.9	Not reported

C1D8: Social Functioning (n=26)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	70.51	Not reported	58.3	82.8	Not reported

C1D8: Fatigue (n=26)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	27.24	Not reported	16.0	38.5	Not reported

C1D8: Nausea and Vomiting (n=26)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	12.82	Not reported	4.9	20.7	Not reported

C1D8: Pain (n=26)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	42.31	Not reported	29.6	55.0	Not reported

C1D8: Dyspnea (n=26)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	30.77	Not reported	18.2	43.4	Not reported

C1D8: Insomnia (n=26)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	43.59	Not reported	29.0	58.2	Not reported

C1D8: Appetite Loss (n=26)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	24.36	Not reported	10.3	38.4	Not reported

C1D8: Constipation (n=26)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	34.62	Not reported	19.2	50.1	Not reported

C1D8: Diarrhea (n=26)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	15.38	Not reported	5.1	25.6	Not reported

C1D8: Financial Problems

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	28.20	Not reported	15.2	41.2	Not reported

C1D15: Global Health Status

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	55.33	Not reported	45.2	65.5	Not reported

C1D15: Physical Functioning (n=25)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	62.93	Not reported	54.1	71.7	Not reported

C1D15: Role Functioning (n=25)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	52.67	Not reported	38.4	66.9	Not reported

C1D15: Emotional Functioning (n=25)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	67.00	Not reported	55.2	78.8	Not reported

C1D15: Cognitive Functioning (n=25)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	68.00	Not reported	56.8	79.2	Not reported

C1D15: Social Functioning (n=25)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	64.00	Not reported	50.3	77.7	Not reported

C1D15: Fatigue (n=25)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	33.00	Not reported	21.2	44.8	Not reported

C1D15: Nausea and Vomiting (n=25)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	20.67	Not reported	10.5	30.8	Not reported

C1D15: Pain (n=25)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	45.33	Not reported	32.7	58.0	Not reported

C1D15: Dyspnea (n=25)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	42.67	Not reported	28.6	56.7	Not reported

C1D15: Insomnia (n=25)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	40.00	Not reported	28.8	51.2	Not reported

C1D15: Appetite Loss (n=25)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	29.33	Not reported	14.8	43.8	Not reported

C1D15: Constipation (n=25)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	32.00	Not reported	16.9	47.1	Not reported

C1D15: Diarrhea (n=25)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	20.00	Not reported	7.4	32.6	Not reported

C1D15: Financial Problems (n=25)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	29.33	Not reported	16.0	42.7	Not reported

C2D1: Global Health Status (n=25)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	52.33	Not reported	42.7	62.0	Not reported

C2D1: Physical Functioning (n=25)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	63.73	Not reported	55.1	72.4	Not reported

C2D1: Role Functioning (n=25)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	60.67	Not reported	50.2	71.2	Not reported

C2D1: Emotional Functioning (n=25)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	65.67	Not reported	53.9	77.5	Not reported

C2D1: Cognitive Functioning (n=25)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	72.00	Not reported	61.7	82.3	Not reported

C2D1: Social Functioning (n=25)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	64.67	Not reported	52.5	76.8	Not reported

C2D1: Fatigue (n=25)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	34.33	Not reported	22.5	46.1	Not reported

C2D1: Nausea and Vomiting (n=25)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	12.67	Not reported	7.0	18.4	Not reported

C2D1: Pain (n=25)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	43.33	Not reported	31.6	55.1	Not reported

C2D1: Dyspnea (n=25)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	33.33	Not reported	22.8	43.8	Not reported

C2D1: Insomnia (n=25)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	40.00	Not reported	28.1	51.9	Not reported

C2D1: Appetite Loss (n=25)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	22.67	Not reported	9.7	35.7	Not reported

C2D1: Constipation (n=25)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	21.33	Not reported	7.1	35.6	Not reported

C2D1: Diarrhea (n=25)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	6.67	Not reported	1.0	12.3	Not reported

C2D1: Financial Problems (n=25)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	29.33	Not reported	14.3	44.4	Not reported

C3D1: Global Health Status (n=25)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	56.82	Not reported	48.1	65.5	Not reported

C3D1: Physical Functioning (n=25)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	68.18	Not reported	59.2	77.2	Not reported

C3D1: Role Functioning (n=22)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	62.88	Not reported	48.5	77.3	Not reported

C3D1: Emotional Functioning (n=22)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	68.56	Not reported	56.5	80.6	Not reported

C3D1: Cognitive Functioning (n=22)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	71.97	Not reported	59.8	84.1	Not reported

C3D1: Social Functioning (n=22)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	70.45	Not reported	57.6	83.3	Not reported

C3D1: Fatigue (n=22)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	31.44	Not reported	19.4	43.5	Not reported

C3D1: Nausea and Vomiting (n=22)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	14.39	Not reported	5.5	23.3	Not reported

C3D1: Pain (n=22)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	30.30	Not reported	16.7	43.9	Not reported

C3D1: Dyspnea (n=22)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	36.36	Not reported	22.0	50.7	Not reported

C3D1: Insomnia (n=22)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	36.36	Not reported	25.3	47.5	Not reported

C3D1: Appetite Loss (n=22)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	22.73	Not reported	12.1	33.3	Not reported

C3D1: Constipation (n=22)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	36.36	Not reported	22.0	50.7	Not reported

C3D1: Diarrhea (n=22)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	6.06	Not reported	-1.3	13.5	Not reported

C3D1: Financial Problems (n=22)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	34.85	Not reported	19.4	50.3	Not reported

C4D1: Global Health Status (n=18)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	59.72	Not reported	49.6	69.8	Not reported

C4D1: Physical Functioning (n=18)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	63.15	Not reported	51.0	75.3	Not reported

C4D1: Role Functioning (n=18)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	60.19	Not reported	44.6	75.8	Not reported

C4D1: Emotional Functioning (n=18)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	67.13	Not reported	53.8	80.5	Not reported

C4D1: Cognitive Functioning (n=18)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	71.30	Not reported	57.7	84.9	Not reported

C4D1: Social Functioning (n=18)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	64.81	Not reported	48.5	81.1	Not reported

C4D1: Fatigue (n=18)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	32.87	Not reported	19.5	46.2	Not reported

C4D1: Nausea and Vomiting (n=18)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	9.26	Not reported	2.2	16.4	Not reported

C4D1: Pain (n=18)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	30.56	Not reported	16.8	44.3	Not reported

C4D1: Dyspnea (n=18)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	37.04	Not reported	24.5	49.6	Not reported

C4D1: Insomnia (n=18)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	35.19	Not reported	19.6	50.7	Not reported

C4D1: Appetite Loss (n=18)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	20.37	Not reported	5.2	35.6	Not reported

C4D1: Constipation (n=18)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	33.33	Not reported	17.3	49.4	Not reported

C4D1: Diarrhea (n=18)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	5.56	Not reported	-3.0	14.1	Not reported

C4D1: Financial Problems (n=18)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	33.33	Not reported	17.3	49.4	Not reported

C5D1:Global Health Status (n=17)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	52.45	Not reported	42.2	62.7	Not reported

C5D1: Physical Functioning (n=17)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	58.04	Not reported	47.1	69.0	Not reported

C5D1: Role Functioning (n=17)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	56.86	Not reported	41.4	72.3	Not reported

C5D1: Emotional Functioning (n=17)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	65.20	Not reported	49.5	80.9	Not reported

C5D1: Cognitive Functioning (n=17)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	67.65	Not reported	52.1	83.2	Not reported

C5D1: Social Functioning (n=17)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	59.80	Not reported	42.9	76.7	Not reported

C5D1: Fatigue (n=17)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	34.80	Not reported	19.1	50.5	Not reported

C5D1: Nausea and Vomiting (n=17)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	11.76	Not reported	4.5	19.0	Not reported

C5D1: Pain (n=17)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	31.37	Not reported	16.3	46.5	Not reported

C5D1: Dyspnea (n=17)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	45.10	Not reported	28.0	62.2	Not reported

C5D1: Insomnia (n=17)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	27.45	Not reported	13.6	41.3	Not reported

C5D1: Appetite Loss (n=17)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	17.65	Not reported	3.9	31.4	Not reported

C5D1: Constipation (n=17)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	35.29	Not reported	18.7	51.9	Not reported

C5D1: Diarrhea (n=17)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	9.80	Not reported	-3.4	23.0	Not reported

C5D1: Financial Problems (n=17)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	27.45	Not reported	9.0	45.9	Not reported

C6D1: Global Health Status (n=15)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	61.11	Not reported	50.8	71.4	Not reported

C6D1: Physical Functioning (n=15)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	65.78	Not reported	55.6	75.9	Not reported

C6D1: Role Functioning (n=15)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	61.11	Not reported	45.3	77.0	Not reported

C6D1: Emotional Functioning (n=15)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	73.89	Not reported	59.1	88.7	Not reported

C6D1: Cognitive Functioning (n=15)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	72.22	Not reported	56.0	88.5	Not reported

C6D1: Social Functioning (n=15)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	71.11	Not reported	55.3	86.9	Not reported

C6D1: Fatigue (n=15)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	26.11	Not reported	11.3	40.9	Not reported

C6D1: Nausea and Vomiting (n=15)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	7.78	Not reported	0.1	15.5	Not reported

C6D1: Pain (n=15)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	27.78	Not reported	14.9	40.7	Not reported

C6D1: Dyspnea (n=15)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	31.11	Not reported	18.1	44.1	Not reported

C6D1: Insomnia (n=15)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	31.11	Not reported	14.8	47.4	Not reported

C6D1: Appetite Loss (n=15)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	11.11	Not reported	-4.0	26.2	Not reported

C6D1: Constipation (n=15)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	28.89	Not reported	10.6	47.2	Not reported

C6D1: Diarrhea (n=15)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	4.44	Not reported	-2.1	10.9	Not reported

C6D1: Financial Problems (n=15)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	26.67	Not reported	9.3	44.0	Not reported

C7D1: Global Health Status (n=11)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	53.79	Not reported	42.2	65.4	Not reported

C7D1: Physical Functioning (n=11)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	56.36	Not reported	42.6	70.1	Not reported

C7D1: Role Functioning (n=11)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	51.52	Not reported	27.8	75.2	Not reported

C7D1: Emotional Functioning (n=11)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	66.67	Not reported	45.3	88.1	Not reported

C7D1: Cognitive Functioning (n=11)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	74.24	Not reported	53.4	95.1	Not reported

C7D1: Social Functioning (n=11)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	68.18	Not reported	46.1	90.3	Not reported

C7D1: Fatigue (n=11)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	33.33	Not reported	11.9	54.7	Not reported

C7D1: Nausea and Vomiting (n=11)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	12.12	Not reported	2.0	22.2	Not reported

C7D1: Pain (n=11)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	37.88	Not reported	13.8	61.9	Not reported

C7D1: Dyspnea (n=11)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	20.00	Not reported	3.3	36.7	Not reported

C7D1: Insomnia (n=11)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	30.30	Not reported	9.2	51.4	Not reported

C7D1: Appetite Loss (n=11)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	6.06	Not reported	-7.4	19.6	Not reported

C7D1: Constipation (n=11)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	27.27	Not reported	7.7	46.8	Not reported

C7D1: Diarrhea (n=11)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	12.12	Not reported	-3.0	27.2	Not reported

C7D1: Financial Problems (n=11)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	27.27	Not reported	5.3	49.3	Not reported

C8D1: Global Health Status (n=10)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	62.50	Not reported	48.7	76.3	Not reported

C8D1: Physical Functioning (n=10)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	56.00	Not reported	39.0	73.0	Not reported

C8D1: Role Functioning (n=10)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	58.33	Not reported	34.3	82.3	Not reported

C8D1: Emotional Functioning (n=10)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	78.33	Not reported	65.4	91.3	Not reported

C8D1: Cognitive Functioning (n=10)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	78.33	Not reported	60.5	96.1	Not reported

C8D1: Social Functioning (n=10)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	73.33	Not reported	57.2	89.4	Not reported

C8D1: Fatigue (n=10)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	21.67	Not reported	8.7	34.6	Not reported

C8D1: Nausea and Vomiting (n=10)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	5.00	Not reported	-0.8	10.8	Not reported

C8D1: Pain (n=10)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	31.67	Not reported	12.6	50.7	Not reported

C8D1: Dyspnea (n=10)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	30.00	Not reported	6.3	53.7	Not reported

C8D1: Insomnia (n=10)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	36.67	Not reported	10.4	62.9	Not reported

C8D1: Appetite Loss (n=10)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	10.00	Not reported	-1.5	21.5	Not reported

C8D1: Constipation (n=10)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	20.00	Not reported	-0.1	40.1	Not reported

C8D1: Diarrhea (n=10)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	0.00	Not reported	0.0	0.0	Not reported

C8D1: Financial Problems (n=10)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	40.00	Not reported	15.4	64.6	Not reported

C9D1: Global Health Status (n=9)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	56.48	Not reported	41.5	71.4	Not reported

C9D1: Physical Functioning (n=9)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	57.78	Not reported	39.5	76.1	Not reported

C9D1: Role Functioning (n=9)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	68.52	Not reported	43.3	93.7	Not reported

C9D1: Emotional Functioning (n=9)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	75.00	Not reported	62.2	87.8	Not reported

C9D1: Cognitive Functioning (n=9)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	72.22	Not reported	49.1	95.3	Not reported

C9D1: Social Functioning (n=9)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	74.07	Not reported	57.0	91.2	Not reported

C9D1: Fatigue (n=9)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	25.00	Not reported	12.2	37.8	Not reported

C9D1: Nausea and Vomiting (n=9)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	5.56	Not reported	-0.9	12.0	Not reported

C9D1: Pain (n=9)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	25.92	Not reported	14.6	37.2	Not reported

C9D1: Dyspnea (n=9)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	33.33	Not reported	11.1	55.5	Not reported

C9D1: Insomnia (n=9)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	40.74	Not reported	19.4	62.1	Not reported

C9D1: Appetite Loss (n=9)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	11.11	Not reported	-7.0	29.2	Not reported

C9D1: Constipation (n=9)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	18.52	Not reported	-0.1	37.1	Not reported

C9D1: Diarrhea (n=9)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	7.41	Not reported	-9.7	24.5	Not reported

C9D1: Financial Problems (n=9)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	40.74	Not reported	12.7	68.7	Not reported

C10D1: Global Health Status (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	52.78	Not reported	26.4	79.1	Not reported

C10D1: Physical Functioning (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	52.22	Not reported	38.6	65.8	Not reported

C10D1: Role Functioning (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	50.00	Not reported	18.7	81.3	Not reported

C10D1: Emotional Functioning (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	70.83	Not reported	42.2	99.4	Not reported

C10D1: Cognitive Functioning (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	75.00	Not reported	48.5	101.5	Not reported

C10D1: Social Functioning (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	83.33	Not reported	61.2	105.5	Not reported

C10D1: Fatigue (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	29.17	Not reported	0.6	57.8	Not reported

C10D1: Nausea and Vomiting (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	2.78	Not reported	-4.4	9.9	Not reported

C10D1: Pain (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	33.33	Not reported	14.2	52.5	Not reported

C10D1: Dyspnea (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	33.33	Not reported	-10.9	77.6	Not reported

C10D1: Insomnia (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	44.45	Not reported	15.9	73.0	Not reported

C10D1: Appetite Loss (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	16.67	Not reported	-12.6	45.9	Not reported

C10D1: Constipation (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	16.67	Not reported	-12.6	45.9	Not reported

C10D1: Diarrhea (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	0.00	Not reported	0.0	0.0	Not reported

C10D1: Financial Problems (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	38.89	Not reported	-12.6	90.4	Not reported

C11D1: Global Health Status (n=5)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	61.67	Not reported	39.0	84.3	Not reported

C11D1: Physical Functioning (n=5)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	54.67	Not reported	39.9	69.5	Not reported

C11D1: Role Functioning (n=5)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	53.33	Not reported	26.3	80.3	Not reported

C11D1: Emotional Functioning (n=5)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	65.00	Not reported	29.6	100.4	Not reported

C11D1: Cognitive Functioning (n=5)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	73.33	Not reported	30.4	116.2	Not reported

C11D1: Social Functioning (n=5)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	66.66	Not reported	37.4	95.9	Not reported

C11D1: Fatigue (n=5)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	35.00	Not reported	-0.4	70.4	Not reported

C11D1: Nausea and Vomiting (n=5)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	6.67	Not reported	-11.8	25.2	Not reported

C11D1: Pain (n=5)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	30.00	Not reported	7.3	52.7	Not reported

C11D1: Dyspnea (n=5)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	20.00	Not reported	-17.0	57.0	Not reported

C11D1: Insomnia (n=5)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	40.00	Not reported	21.5	58.5	Not reported

C11D1: Appetite Loss (n=5)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	13.33	Not reported	-9.3	36.0	Not reported

C11D1: Constipation (n=5)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	13.33	Not reported	-23.7	50.4	Not reported

C11D1: Diarrhea (n=5)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	6.67	Not reported	-11.8	25.2	Not reported

C11D1: Financial Problems (n=5)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	26.67	Not reported	-18.7	72.0	Not reported

C12D1: Global Health Status (n=15)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	45.00	Not reported	9.5	80.5	Not reported

C12D1: Physical Functioning (n=15)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	52.00	Not reported	36.1	67.9	Not reported

C12D1: Role Functioning (n=15)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	43.33	Not reported	8.7	78.0	Not reported

C12D1: Emotional Functioning (n=15)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	63.33	Not reported	20.9	105.7	Not reported

C12D1: Cognitive Functioning (n=15)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	70.00	Not reported	43.0	97.0	Not reported

C12D1: Social Functioning (n=15)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	50.00	Not reported	24.7	75.3	Not reported

C12D1: Fatigue (n=15)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	36.67	Not reported	-5.7	79.1	Not reported

C12D1: Nausea and Vomiting (n=15)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	6.67	Not reported	-11.8	25.2	Not reported

C12D1: Pain (n=15)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	43.33	Not reported	24.8	61.8	Not reported

C12D1: Dyspnea (n=15)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	40.00	Not reported	-14.0	94.0	Not reported

C12D1: Insomnia (n=15)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	33.33	Not reported	4.1	62.6	Not reported

C12D1: Appetite Loss (n=15)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	26.67	Not reported	-8.0	61.3	Not reported

C12D1: Constipation (n=15)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	6.67	Not reported	-11.8	25.2	Not reported

C12D1: Diarrhea (n=15)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	13.33	Not reported	-9.3	36.0	Not reported

C12D1: Financial Problems (n=15)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	46.67	Not reported	-0.5	93.9	Not reported

C13D1: Global Health Status (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	54.17	Not reported	27.2	81.1	Not reported

C13D1: Physical Functioning (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	53.34	Not reported	38.0	68.7	Not reported

C13D1: Role Functioning (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	55.56	Not reported	19.4	91.7	Not reported

C13D1: Emotional Functioning (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	69.44	Not reported	32.5	106.4	Not reported

C13D1: Cognitive Functioning (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	69.44	Not reported	39.3	99.6	Not reported

C13D1: Social Functioning (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	61.11	Not reported	34.8	87.4	Not reported

C13D1: Fatigue (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	30.56	Not reported	-6.4	67.5	Not reported

C13D1: Nausea and Vomiting (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	5.56	Not reported	-8.7	19.8	Not reported

C13D1: Pain (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	27.78	Not reported	9.7	45.8	Not reported

C13D1: Dyspnea (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	22.22	Not reported	-6.3	50.8	Not reported

C13D1: Insomnia (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	27.78	Not reported	-6.6	62.2	Not reported

C13D1: Appetite Loss (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	16.67	Not reported	-2.5	35.8	Not reported

C13D1: Constipation (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	16.67	Not reported	-12.6	45.9	Not reported

C13D1: Diarrhea (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	22.22	Not reported	-20.1	64.6	Not reported

C13D1: Financial Problems (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	38.89	Not reported	-2.0	79.8	Not reported

C14D1: Global Health Status (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	61.11	Not reported	43.9	78.3	Not reported

C14D1: Physical Functioning (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	54.45	Not reported	40.9	68.0	Not reported

C14D1: Role Functioning (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	50.00	Not reported	27.9	72.1	Not reported

C14D1: Emotional Functioning (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	73.61	Not reported	45.7	101.5	Not reported

C14D1: Cognitive Functioning (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	83.33	Not reported	61.2	105.5	Not reported

C14D1: Social Functioning (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	69.45	Not reported	41.4	97.5	Not reported

C14D1: Fatigue (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	26.39	Not reported	-1.5	54.3	Not reported

C14D1: Nausea and Vomiting (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	2.78	Not reported	-4.4	9.9	Not reported

C14D1: Pain (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	33.33	Not reported	14.2	52.5	Not reported

C14D1: Dyspnea (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	22.22	Not reported	4.2	40.3	Not reported

C14D1: Insomnia (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	22.22	Not reported	-6.3	50.8	Not reported

C14D1: Appetite Loss (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	0.00	Not reported	0.0	0.0	Not reported

C14D1: Constipation (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	16.67	Not reported	-12.6	45.9	Not reported

C14D1: Diarrhea (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	5.56	Not reported	-8.7	19.8	Not reported

C14D1: Financial Problems (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	33.33	Not reported	-10.9	77.6	Not reported

C15D1: Global Health Status (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	66.67	Not reported	52.0	81.3	Not reported

C15D1: Physical Functioning (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	52.23	Not reported	40.2	64.3	Not reported

C15D1: Role Functioning (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	61.11	Not reported	34.8	87.4	Not reported

C15D1: Emotional Functioning (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	61.11	Not reported	56.6	99.0	Not reported

C15D1: Cognitive Functioning (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	72.22	Not reported	39.7	104.8	Not reported

C15D1: Social Functioning (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	66.67	Not reported	35.4	98.0	Not reported

C15D1: Fatigue (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	22.22	Not reported	1.0	43.4	Not reported

C15D1: Nausea and Vomiting (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	2.78	Not reported	-4.4	9.9	Not reported

C15D1: Pain (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	27.78	Not reported	3.9	51.7	Not reported

C15D1: Dyspnea (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	27.78	Not reported	1.4	54.1	Not reported

C15D1: Insomnia (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	22.22	Not reported	4.2	40.3	Not reported

C15D1: Appetite Loss (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	5.56	Not reported	-8.7	19.8	Not reported

C15D1: Constipation (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	16.67	Not reported	-12.6	45.9	Not reported

C15D1: Diarrhea (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	5.56	Not reported	-8.7	19.8	Not reported

C15D1: Financial Problems (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	44.45	Not reported	2.1	86.8	Not reported

C16D1: Global Health Status (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	52.78	Not reported	28.9	76.7	Not reported

C16D1: Physical Functioning (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	55.56	Not reported	46.0	65.1	Not reported

C16D1: Role Functioning (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	50.00	Not reported	30.8	69.2	Not reported

C16D1: Emotional Functioning (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	76.39	Not reported	47.4	105.4	Not reported

C16D1: Cognitive Functioning (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	77.78	Not reported	56.6	99.0	Not reported

C16D1: Social Functioning (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	69.44	Not reported	37.3	101.5	Not reported

C16D1: Fatigue (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	23.61	Not reported	-5.4	52.6	Not reported

C16D1: Nausea and Vomiting (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	0.00	Not reported	0.0	0.0	Not reported

C16D1: Pain (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	33.33	Not reported	8.6	58.1	Not reported

C16D1: Dyspnea (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	27.78	Not reported	1.4	54.1	Not reported

C16D1: Insomnia (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	27.78	Not reported	1.4	54.1	Not reported

C16D1: Appetite Loss (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	5.56	Not reported	-8.7	19.8	Not reported

C16D1: Constipation (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	11.11	Not reported	-17.5	39.7	Not reported

C16D1: Diarrhea (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	22.22	Not reported	-6.3	50.8	Not reported

C16D1: Financial Problems (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	44.45	Not reported	2.1	86.8	Not reported

C17D1: Global Health Status (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	55.56	Not reported	35.1	76.0	Not reported

C17D1: Physical Functioning (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	51.11	Not reported	32.5	69.7	Not reported

C17D1: Role Functioning (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	58.34	Not reported	43.7	73.0	Not reported

C17D1: Emotional Functioning (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	73.61	Not reported	44.1	103.1	Not reported

C17D1: Cognitive Functioning (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	72.22	Not reported	43.7	100.8	Not reported

C17D1: Social Functioning (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	72.22	Not reported	45.9	98.6	Not reported

C17D1: Fatigue (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	26.39	Not reported	-3.1	55.9	Not reported

C17D1: Nausea and Vomiting (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	2.78	Not reported	-4.4	9.9	Not reported

C17D1: Pain (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	30.56	Not reported	2.5	58.6	Not reported

C17D1: Dyspnea (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	22.22	Not reported	-6.3	50.8	Not reported

C17D1: Insomnia (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	50.00	Not reported	7.2	92.8	Not reported

C17D1: Appetite Loss (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	5.56	Not reported	-8.7	19.8	Not reported

C17D1: Constipation (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	22.22	Not reported	-13.9	58.4	Not reported

C17D1: Diarrhea (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	5.56	Not reported	-8.7	19.8	Not reported

C17D1: Financial Problems (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	44.45	Not reported	2.1	86.8	Not reported

C18D1: Global Health Status (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	61.11	Not reported	43.9	78.3	Not reported

C18D1: Physical Functioning (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	48.89	Not reported	37.5	60.3	Not reported

C18D1: Role Functioning (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	50.00	Not reported	25.3	74.7	Not reported

C18D1: Emotional Functioning (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	70.83	Not reported	34.7	107.0	Not reported

C18D1: Cognitive Functioning (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	61.11	Not reported	18.7	103.5	Not reported

C18D1: Social Functioning (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	63.89	Not reported	31.8	96.0	Not reported

C18D1: Fatigue (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	29.17	Not reported	-7.0	65.3	Not reported

C18D1: Nausea and Vomiting (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	8.33	Not reported	-13.1	29.8	Not reported

C18D1: Pain (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	61.11	Not reported	25.0	97.2	Not reported

C18D1: Dyspnea (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	33.33	Not reported	11.2	55.5	Not reported

C18D1: Insomnia (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	33.33	Not reported	2.0	64.6	Not reported

C18D1: Appetite Loss (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	22.22	Not reported	-6.3	50.8	Not reported

C18D1: Constipation (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	22.22	Not reported	-13.9	58.4	Not reported

C18D1: Diarrhea (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	5.56	Not reported	-8.7	19.8	Not reported

C18D1: Financial Problems (n=6)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	44.44	Not reported	-3.4	92.2	Not reported

C19D1: Global Health Status (n=4)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	45.83	Not reported	20.4	71.2	Not reported

C19D1: Physical Functioning (n=4)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	45.00	Not reported	23.1	66.9	Not reported

C19D1: Role Functioning (n=4)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	37.50	Not reported	-7.8	82.8	Not reported

C19D1: Emotional Functioning (n=4)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	66.67	Not reported	9.4	124.0	Not reported

C19D1: Cognitive Functioning (n=4)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	45.83	Not reported	-39.1	130.7	Not reported

C19D1: Social Functioning (n=4)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	50.00	Not reported	12.5	87.5	Not reported

C19D1: Fatigue (n=4)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	33.33	Not reported	-24.0	90.6	Not reported

C19D1: Nausea and Vomiting (n=4)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	12.50	Not reported	-12.9	37.9	Not reported

C19D1: Pain (n=4)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	58.33	Not reported	24.1	92.6	Not reported

C19D1: Dyspnea (n=4)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	25.00	Not reported	-1.5	51.5	Not reported

C19D1: Insomnia (n=4)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	41.67	Not reported	-25.1	108.4	Not reported

C19D1: Appetite Loss (n=4)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	25.00	Not reported	-1.5	51.5	Not reported

C19D1: Constipation (n=4)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	50.00	Not reported	-18.5	118.5	Not reported

C19D1: Diarrhea (n=4)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	0.00	Not reported	0.0	0.0	Not reported

C19D1: Financial Problems (n=4)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	41.67	Not reported	-25.1	108.4	Not reported

C20D1: Global Health Status (n=2)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	37.50	Not reported	-15.5	90.5	Not reported

C20D1: Physical Functioning (n=2)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	46.67	Not reported	-38.0	131.4	Not reported

C20D1: Role Functioning (n=2)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	33.33	Not reported	33.3	33.4	Not reported

C20D1: Emotional Functioning (n=2)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	33.33	Not reported	-284	351.0	Not reported

C20D1: Cognitive Functioning (n=2)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	16.67	Not reported	16.6	16.7	Not reported

C20D1: Social Functioning (n=2)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	41.67	Not reported	-64.2	147.6	Not reported

C20D1: Fatigue (n=2)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	66.67	Not reported	-251	384.3	Not reported

C20D1: Nausea and Vomiting (n=2)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	16.67	Not reported	-195	228.4	Not reported

C20D1: Pain (n=2)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	66.67	Not reported	66.6	66.7	Not reported

C20D1: Dyspnea (n=2)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	33.34	Not reported	-390	456.9	Not reported

C20D1: Insomnia (n=2)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	50.00	Not reported	-162	261.8	Not reported

C20D1: Appetite Loss (n=2)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	33.33	Not reported	33.3	33.4	Not reported

C20D1: Constipation (n=2)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	16.67	Not reported	-195	228.4	Not reported

C20D1: Diarrhea (n=2)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	16.67	Not reported	-195	228.4	Not reported

C20D1: Financial Problems (n=2)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	83.34	Not reported	-128	295.1	Not reported

C21D1: Global Health Status (n=1)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	41.67	Not reported	NA	NA	95% Confidence Interval (CI) was not estimable since only 1 participant was evaluable.

C21D1: Physical Functioning (n=1)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	53.33	Not reported	NA	NA	95% CI was not estimable since only 1 participant was evaluable.

C21D1: Role Functioning (n=1)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	50.00	Not reported	NA	NA	95% CI was not estimable since only 1 participant was evaluable.

C21D1: Emotional Functioning (n=1)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	66.67	Not reported	NA	NA	95% CI was not estimable since only 1 participant was evaluable.

C21D1: Cognitive Functioning (n=1)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	0.00	Not reported	NA	NA	95% CI was not estimable since only 1 participant was evaluable.

C21D1: Social Functioning (n=1)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	33.33	Not reported	NA	NA	95% CI was not estimable since only 1 participant was evaluable.

C21D1: Fatigue (n=1)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	33.33	Not reported	NA	NA	95% CI was not estimable since only 1 participant was evaluable.

C21D1: Nausea and Vomiting (n=1)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	33.33	Not reported	NA	NA	95% CI was not estimable since only 1 participant was evaluable.

C21D1: Pain (n=1)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	66.67	Not reported	NA	NA	95% CI was not estimable since only 1 participant was evaluable.

C21D1: Dyspnea (n=1)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	0.00	Not reported	NA	NA	95% CI was not estimable since only 1 participant was evaluable.

C21D1: Insomnia (n=1)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	66.67	Not reported	NA	NA	95% CI was not estimable since only 1 participant was evaluable.

C21D1: Appetite Loss (n=1)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	33.33	Not reported	NA	NA	95% CI was not estimable since only 1 participant was evaluable.

C21D1: Constipation (n=1)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	0.00	Not reported	NA	NA	95% CI was not estimable since only 1 participant was evaluable.

C21D1: Diarrhea (n=1)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	0.00	Not reported	NA	NA	95% CI was not estimable since only 1 participant was evaluable.

C21D1: Financial Problems (n=1)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	100.00	Not reported	NA	NA	95% CI was not estimable since only 1 participant was evaluable.

C22D1: Global Health Status (n=1)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	16.67	Not reported	NA	NA	95% CI was not estimable since only 1 participant was evaluable.

C22D1: Physical Functioning (n=1)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	53.33	Not reported	NA	NA	95% CI was not estimable since only 1 participant was evaluable.

C22D1: Role Functioning (n=1)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	50.00	Not reported	NA	NA	95% CI was not estimable since only 1 participant was evaluable.

C22D1: Emotional Functioning (n=1)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	83.33	Not reported	NA	NA	95% CI was not estimable since only 1 participant was evaluable.

C22D1: Cognitive Functioning (n=1)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	33.33	Not reported	NA	NA	95% CI was not estimable since only 1 participant was evaluable.

C22D1: Social Functioning (n=1)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	33.33	Not reported	NA	NA	95% CI was not estimable since only 1 participant was evaluable.

C22D1: Fatigue (n=1)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	16.67	Not reported	NA	NA	95% CI was not estimable since only 1 participant was evaluable.

C22D1: Nausea and Vomiting (n=1)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	33.33	Not reported	NA	NA	95% CI was not estimable since only 1 participant was evaluable.

C22D1: Pain (n=1)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	83.33	Not reported	NA	NA	95% CI was not estimable since only 1 participant was evaluable.

C22D1: Dyspnea (n=1)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	0.00	Not reported	NA	NA	95% CI was not estimable since only 1 participant was evaluable.

C22D1: Insomnia (n=1)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	33.33	Not reported	NA	NA	95% CI was not estimable since only 1 participant was evaluable.

C22D1: Appetite Loss (n=1)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	0.00	Not reported	NA	NA	95% CI was not estimable since only 1 participant was evaluable.

C22D1: Constipation (n=1)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	0.00	Not reported	NA	NA	95% CI was not estimable since only 1 participant was evaluable.

C22D1: Diarrhea (n=1)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	0.00	Not reported	NA	NA	95% CI was not estimable since only 1 participant was evaluable.

C22D1: Financial Problems (n=1)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	100.00	Not reported	NA	NA	95% CI was not estimable since only 1 participant was evaluable.

End of treatment: Global health status (n=17)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	49.02	Not reported	34.7	63.4	Not reported

End of Treatment: Physical Functioning (n=17)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	56.08	Not reported	45.0	67.2	Not reported

End of Treatment: Role Functioning (n=17)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	56.86	Not reported	38.4	75.3	Not reported

End of Treatment: Emotional Functioning (n=17)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	62.26	Not reported	49.1	75.4	Not reported

End of Treatment: Cognitive Functioning (n=17)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	62.75	Not reported	48.7	76.8	Not reported

End of Treatment: Social Functioning (n=17)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	65.69	Not reported	48.2	83.2	Not reported

End of Treatment: Fatigue (n=17)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	37.74	Not reported	24.6	50.9	Not reported

End of Treatment: Nausea and Vomiting (n=17)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	16.67	Not reported	4.5	28.8	Not reported

End of Treatment: Pain (n=17)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	43.14	Not reported	26.0	60.3	Not reported

End of Treatment: Dyspnea (n=17)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	41.18	Not reported	24.5	57.8	Not reported

End of Treatment: Insomnia (n=17)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	49.02	Not reported	30.7	67.3	Not reported

End of Treatment: Appetite Loss (n=17)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	25.49	Not reported	10.0	41.0	Not reported

End of Treatment: Constipation (n=17)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	43.14	Not reported	27.4	58.9	Not reported

End of Treatment: Diarrhea (n=17)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	5.88	Not reported	-3.2	14.9	Not reported

End of Treatment: Financial Problems (n=17)

Values in units on a scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)	45.10	Not reported	27.0	63.2	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
50.7
upper Limit
70.9
value
60.80
title
C1D1: Global Health Status (n=27)
categories
measurements
group Id
OG000
lower Limit
55.6
upper Limit
72.8
value
64.20
title
C1D1: Physical Functioning (n=27)
categories
measurements
group Id
OG000
lower Limit
46.8
upper Limit
73.0
value
59.88
title
C1D1: Role Functioning (n=27)
categories
measurements
group Id
OG000
lower Limit
59.8
upper Limit
80.9
value
70.37
title
C1D1: Emotional Functioning (n=27)
categories
measurements
group Id
OG000
lower Limit
62.0
upper Limit
82.4
value
72.22
title
C1D1: Cognitive Functioning (n=27)
categories
measurements
group Id
OG000
lower Limit
57.6
upper Limit
80.7
value
69.14
title
C1D1: Social Functioning (n=27)
categories
measurements
group Id
OG000
lower Limit
19.1
upper Limit
40.2
value
29.63
title
C1D1: Fatigue (n=27)
categories
measurements
group Id
OG000
lower Limit
2.2
upper Limit
11.4
value
6.79
title
C1D1: Nausea and Vomiting (n=27)
categories
measurements
group Id
OG000
lower Limit
22.0
upper Limit
49.6
value
35.80
title
C1D1: Pain (n=27)
categories
measurements
group Id
OG000
lower Limit
21.4
upper Limit
42.7
value
32.10
title
C1D1: Dyspnea (n=27)
categories
measurements
group Id
OG000
lower Limit
29.1
upper Limit
57.3
value
43.21
title
C1D1: Insomnia (n=27)
categories
measurements
group Id
OG000
lower Limit
8.8
upper Limit
33.2
value
20.99
title
C1D1: Appetite Loss (n=27)

denoms

counts
group Id
OG000
value
27
units
Participants

description

dispersion Type

95% Confidence Interval

groups

description
Palbociclib (PD 0332991) 100 mg capsule orally once daily for 12 days followed by 9 days off-treatment in a 21-day cycle along with bortezomib 1.0 mg/m\^2 intravenous injection and dexamethasone 20 mg tablet orally 30 minutes prior to bortezomib injection on Day 8, 11, 15 and 18 of 21-day cycle (schedule B) during Phase 2 of the study. Treatment was continued until any of the following withdrawal criteria was met: disease progression (unless the investigator judged that participant could still derive clinical benefit from continuing the treatment and the risk/benefit was still favorable), unacceptable toxicities, need for surgery or radiation therapy considered due to progressive disease by investigator, investigator conclusion that it is in the participant's best interest to discontinue therapy, need for anti-cancer therapy, lost to follow-up, withdrawal from treatment, or withdrawal of consent.
id
OG000
title
Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:Schedule B)

param Type

MEAN

population Description

Patient Reported Outcomes (PRO) analysis set included all enrolled participants who received study treatment, had a baseline PRO assessment, and completed at least 1 on-study PRO assessment. Here 'n' signifies those participants who were evaluable at specified time points for each arm, respectively.

reporting Status

POSTED

time Frame

C1D1 (baseline), C1D8, C1D15, C2D1, C3D1, C4D1, C5D1, C6D1, C7D1, C8D1, C9D1, C10D1, C11D1, C12D1, C13D1, C14D1, C15D1, C16D1, C17D1, C18D1, C19D1, C20D1, C21D1, C22D1, End of Treatment (assessment at early withdrawal occurring up to Cycle 22)

title

European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (EORTC QLQ-C30): Phase 2

type

SECONDARY

unit Of Measure

units on a scale

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice